Combination of cellular immunotherapy
AssigneeCrage Medical Co., Limited
InventorsZonghai Li, Xiuqi Wu
Life of this patent
Estimating the term…
Abstract
Provided in the present invention is a method for treating tumor. An immune effector cell and a second treatment agent are applied to individual suffering from tumor, wherein the immune effector cell expresses a receptor for recognizing tumor antigen, and wherein the second treatment agent is a compound of formula I or a pharmaceutically acceptable salt thereof.
Claims16
A method for treating a tumor or for reducing the growth, survival or viability of cancer cells, characterized in that an immune effector cell and a second therapeutic agent are administered to a human suffering from a tumor, wherein the immune effector cell expresses a receptor recognizing glypican-3 (GPC3) and the second therapeutic agent comprises a compound of formula II:
- wherein the immune effector cell is a T cell,
- wherein the receptor comprises a chimeric antigen receptor (CAR),
- wherein the chimeric antigen receptor comprises an antibody or a fragment thereof that specifically recognizes a tumor antigen, the transmembrane region of CD28, the co-stimulatory signal domain of CD28, and the intracellular domain of CD3ζ,
- wherein the antibody specifically recognizing a tumor antigen comprises HCDR1, HCDR2, HCDR3 respectively represented by SEQ ID NOs:
- 15, 16, 17, and LCDR1, LCDR2, LCDR3 respectively represented by SEQ ID NOs:
- 18, 19, 20.
A kit for treating a tumor, characterized in that the kit comprises:
- 1) an immune effector cell expressing a receptor that recognizes glypican-3 (GPC3),
- wherein the immune effector cell is a T cell,
- wherein the receptor comprises a chimeric antigen receptor (CAR),
- wherein the chimeric antigen receptor comprises an antibody or a fragment thereof that specifically recognizes a tumor antigen, the transmembrane region of CD28, the co-stimulatory signal domain of CD28, and the intracellular domain of CD3ζ,
- wherein the antibody specifically recognizing a tumor antigen comprises HCDR1, HCDR2, HCDR3 respectively represented by SEQ ID NOs:
- 15, 16, 17, and LCDR1, LCDR2, LCDR3 respectively represented by SEQ ID NOs:
- 18, 19, 20;
- 2) a second therapeutic agent;
- 3) a container for containing the above substances of 1) and 2);
- and
- 4) instructions for using the kit to treat a tumor in a human;
- wherein the immune effector cell and the second therapeutic agent comprises a compound of formula II:
Dependencies are inferred from the claim text.